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Abstract: Background: Studies on clinical features, treatment and prognosis of patients with congestive heart failure 
(CHF) and preserved left ventricular ejection fraction (LVEF) are few and their results frequently conflicting.  
Aims: To investigate the characteristics and long term prognosis of patients with CHF and preserved ( 45%) LVEF.  
Methods and Results:  We conducted a prospective multicentre study with 4720 patients attended in 62 heart failure 
clinics from 1999 to 2003 in Spain (BADAPIC registry). LVEF was preserved in 30% patients. Age, female gender, 
prevalence of atrial fibrillation, hypertension and non-ischaemic cardiopathy were all significantly greater in patients with 
preserved LVEF. Mean follow-up was 40±12 months. Mortality and other cardiovascular complication rates during follow 
up were similar in both groups. On multivariate analysis ejection fraction was not an independent predictor for mortality. 
Survival at one and five years was similar in both groups (79% and 59% for patients with preserved LVEF and 78% and 
57% for those with reduced LVEF, respectively).  
Conclusions: In the BADAPIC registry, a high percentage of heart failure patients had preserved LVEF. Although clinical 
differences were seen between groups, morbidity and mortality were similar in both groups. 
Keywords: Heart failure, preserved systolic function, multicentre study. 
INTRODUCTION 
  Congestive heart failure (CHF) is a major health problem 
and is associated with high morbidity and mortality [1]. Its 
incidence and prevalence continue to rise due to the gradual 
ageing of the population, health care improvements and 
survival of patients with chronic diseases such as hyper-
tension and ischaemic heart disease [2, 3]. It is noteworthy, 
however, that mortality of patients with CHF has not been 
significantly reduced despite advances in treatment derived 
from clinical trials [4, 5]. This is probably due to the greater 
age of patients and the comorbidity they commonly 
experience [6].  
  It is estimated that between 20-50% of patients with CHF 
have preserved systolic function (usually defined as a normal 
left ventricular ejection fraction [LVEF]) [6-11]. Several 
studies have reported that in this group there are greater 
proportions of women, elderly and hypertensive patients than 
among patients with CHF and reduced LVEF and a smaller 
proportion of patients with prior myocardial infarction [7, 
10, 12]. 
  Controversy exists over whether such patients have better 
survival than those with CHF and reduced LVEF. Some 
authors [7, 10, 11, 14] report greater morbidity and mortality 
among the latter, whereas others [3, 13, 15] report no such 
findings. The results of previous studies have been 
inconsistent or conflicting, and the estimates of rates of   
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mortality and readmissions vary widely, since they are 
derived from heterogeneous populations with different 
inclusion criteria.  
  Eight years ago the Working Group on Heart Failure, 
Heart Transplantation and Other Therapeutic Alternatives of 
the Spanish Society of Cardiology set up a voluntary registry 
of heart failure units, the BADAPIC Registry (an acronym in 
Spanish for “database of patients with heart failure”). The 
initial results of the registry have been published elsewhere 
[16]. In the present study we describe the clinical charac-
teristic and long term survival of patients included in the 
BADAPIC Registry with preserved LVEF and compared to 
those with reduced LVEF.  
METHODS 
  The BADAPIC Registry is the official registry of the 
Working Group on Heart Failure, Heart Transplantation and 
Other Therapeutic Alternatives of the Spanish Society of 
Cardiology. The registry, set up in 1999 by the Working 
Group on Heart Failure, is voluntary and so far includes the 
participation of 62 centres from all over Spain that have 
specific heart failure units or clinics. The organization and 
structure of these units vary greatly. The database includes 
more than 100 variables dealing with the main demographic, 
clinical and analytical characteristics, as well as functional 
tests, pharmacological and non-pharmacological therapy, and 
the evolution of the patient. Since the start of the registry, the 
data have been collected annually at the end of the year. The 
data presented here correspond to those collected from 1999 
until 2003 and includes the data on 4720 patients from 62 
heart failure units or clinics throughout Spain. Among these 
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consider as LVEF  45%. Diagnosis of chronic heart failure 
was based on the Framingham criteria. For patients with 
LVEF  45%, evidence of diastolic impairment assessed by 
doppler echocardiography was required.  
Characteristics of the Participating Units 
  Of the 62 hospitals, 14 (22%) are community hospitals 
and 48 (78%) general hospitals; 21% of the registered 
patients were from the community hospitals and 79% from 
the general hospitals. Only 10 (16%) of the participating 
hospitals have a heart transplantation program. Although 
most units are integrated in cardiology departments, eight 
(13% of total) are managed by internists.  
Data Collected 
  For all patients in the study, data were collected during 
the first visit to the heart failure clinic (either during hospital 
admission or as an outpatient). Follow-up data was obtained 
in the following visits to the unit. In the case of patients 
admitted more than once during the study period, the index 
admission considered was the first during which systolic 
function had been evaluated. The frequency of the visits 
depended on the clinical judgement of each participating 
physician, although the follow-up data (change in treatment 
and clinical events) were provided annually by each centre. 
The follow-up data analysed included mortality, admissions 
for heart failure, acute myocardial infarction, coronary 
revascularization, valve surgery or heart transplant.  
Aetiological Evaluation 
  The aetiology of heart failure was established in each 
case by the treating physician at each centre. Ischaemic heart 
disease was defined by the presence of clinical, electro-
cardiographic, or angiographic data suggestive of ischaemia 
or myocardial necrosis. Valve disease was diagnosed if it 
had been previously diagnosed or if it was indicated by 
echocardiographic or catheterisation studies (note, however, 
that the study did not include patients who had been admitted 
to the unit because of severe valve pathology). Arterial 
hypertension was diagnosed if it had been previously 
diagnosed or if the patient had been taking or needed 
antihypertensive drugs to control blood pressure. Dilated 
cardiomyopathy was diagnosed if the patient had 
deteriorated systolic function and a dilated left ventricle but 
no evidence of ischaemic cardiopathy, valve disease, or 
arterial hypertension. Although more than one aetiological 
cause may have been present in a single patient, the 
physician selected the cause considered to be the most 
important in that particular patient. Heart failure with 
preserved systolic function was diagnosed when LVEF was 
equal to or higher than 45% and reduced systolic function 
when LVEF was < 45% (whatever the aetiology) measured 
by echocardiography, radionuclide ventriculography or 
angiography. Assesment of LVEF was done by 
echocardiography in 69%, radionuclide ventriculography in 
16% and angiography in 15%. 
Statistical Analysis 
  Qualitative variables are shown as percentages and 
quantitative variables as means±1 standard deviation. 
Comparison of the differences between the various 
subgroups of patients was made using the Chi-square test or 
Fisher exact test for qualitative variables and the Student t 
test for continuous variables (all of which showed a normal 
distribution). The probability of survival and events during 
the follow-up were estimated by the Kaplan-Meier test and 
compared using the Mantel log-rank test. Given the different 
follow-up times of the two subgroups, the incidence of 
events was adjusted for the total observation time of each; 
results are expressed as incidence per 100 patients per year 
of observation. The incidence of events in both groups was 
compared by the difference in their rates using the Ulm 
method [17]; the 95% confidence intervals (CI) for these rate 
differences were determined by the Sahai and Kurshid 
method [18]. A multivariate analysis using the Cox 
proportional-hazards method was made. Candidate variables 
were included in the initial Cox regression model if they 
were associated with death in an univariate analysis (p<0.1). 
A p<0.05 was considered statistically significant.  
Results 
  As mentioned, the registry included data for 4720 
patients enrolled between 1999 and 2003 from 62 heart 
failure units or clinics throughout Spain. The mean age of 
patients was 66±12 years. The most common age group was 
the decade from 70-79 years, with 9% (425 patients) aged 80 
years or older; the percentage of patients younger than 50 
years of age was very low (11%, 519 patients). Sixty-seven 
percent of patients (3162) were men and 33% (1558) were 
women. 
 Table  1 shows the clinical characteristics of patients in 
the registry. The most common underlying heart condition 
among patients with preserved LVEF was arterial 
hypertension (66%) whereas in the group with reduced 
LVEF was ischaemic cardiomyopathy (47%). Patients with 
preserved LVEF were on average 7 years older, were more 
likely to be female and were more frequently in permanent 
atrial fibrillation. Hyperlipidemia, coronary artery disease, 
prior myocardial infarction or revascularization were all 
more prevalent in the group with reduced LVEF. On the 
other hand, anemia (haemoglobin < 12 g/dl) was more 
frequent in patients with preserved LVEF (23% vs. 17%, 
p<0.05) although differences in renal dysfunction was not 
significantly different between groups (9% vs. 10% 
respectively).  
  There were also significant differences between the two 
groups regarding the medication prescribed after the initial 
visit to the heart failure unit. As shown in Table 2, ACE 
inhibitors, beta blockers and spironolactone were prescribed 
significantly more often to patients with reduced LVEF. 
Carvedilol was the most commonly prescribed drug among 
the beta-blockers, enalapril among the ACE inhibitors, 
losartan among the ARB type II, furosemide among the 
diuretics, aspirin among the anti-platelet aggregating agents, 
amiodarone among the anti-arrhythmic agents, and 
amlodipine among the calcium antagonists. Only very slight 
variation was seen during the follow-up in the percentages of 
the pharmacological agents used. Patients with preserved 
LVEF received on average less doses for carvedilol 
(19mg/day on average vs. 35 mg/day, p<0.001) and less 
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No significant differences were seen in the dose of enalapril 
or furosemide.  
Morbidity and Mortality during Follow-up 
  Survival data were available for all 4720 patients 
enrolled in the registry. After a mean follow-up period of 
40±12 months, 1880 patients had al least one cardiovascular 
event. Mean follow-up period was similar between groups 
(42±13 months in patients with preserved LVEF and 39±12 
months in patients with reduced LVEF). A total of 1416 
deaths (30%) occurred during follow-up: 912 (64%) patients 
died because of worsening heart failure, 340 patients (24%) 
because of sudden death, 99 patients (7%) due to acute 
Table 1.  Clinical Features of 4720 Patients included in the BADAPIC Registry according to LVEF 
 
  LVEF45% 
N=1416 
LVEF<45% 
N=3304 
p-value 
Age, years (SD)  71(12)  64(12)  0.001 
Sex Female (%)   53  28  0.001 
Ejection Fraction, %(SD)  58(10)  30(7)  0.001 
Aetiology (%) 
 Ischaemic 
 High blood pressure 
 Idiopathic Dilated cardiomyopathy 
Other  
 
25 
31 
8 
36 
 
44 
10 
32 
14 
0.001 
High Blood Pressure (%)  66  49  0.001 
Hyperlipidemia (%)  36  41  0.012 
Diabetes Mellitus (%)  36  31  0.023 
Coronary Artery Disease (%)  32  47  0.001 
Prior AMI (%)  18  40  0.001 
Coronary Revascularization  12  19  0.001 
NYHA functional class (%) 
II 
III-IV 
 
77 
23 
 
71 
29 
NS 
Prior admission for heart failure (%)  68  72  NS 
Cardiac rhythm on EKG (%) 
Sinus 
Atrial Fibrillation 
 
54 
46 
 
70 
30 
0.001 
Anemia (Hb<12 g/dl) (%)  23  17  0.05 
Renal dysfunction (Cr>2mg/dl) (%)  9  10  NS 
Table 2.  Pharmacological Treatment following the Initial Visit, according to LVEF 
 
  LVEF45% 
N=1416 
LVEF<45% 
N=3304 
p-value 
Diuretics, n (%)  1218 (86)  2841 (86)  NS 
Digoxin, n (%)  566 (40)  1619 (49)  NS 
ACE inhibitors, n (%)  892 (63)  2709 (82)  0.001 
ARB, n (%)  368 (26)  694 (21)  NS 
Spironolactone, n (%)  1416 (30)  1487 (45)  0.001 
Betablockers, n (%)  694 (49)  2445 (74)  0.001 
Calcium antagonists, n (%)  354 (25)  264 (8)  0.05 
Nitratates, n (%)  396 (28)  991 (30)  NS 
Antiarrhythmics, n (%)  184 (13)  463 (14)%  NS 
Anticoagulation, n (%)  651 (46)  1520 (46)  NS 
Antiaggregants, n (%)  665 (47)  1586 (48)  NS 
Statins, n (%)  396 (28)  1090 (33)  NS Outcome of Heart Failure with Preserved Ejection Fraction  Current Cardiology Reviews, 2009, Vol. 5, No. 4    337 
myocardial infarction and 65 patients (5%) because of other 
non cardiovascular reasons.  
 Table  3 shows the results of the event incidence analysis 
for both groups (expressed as numbers per 100 persons per 
year of observation). Total mortality and mortality due to 
worsening heart failure were similar between groups as was 
the incidence of readmission due to cardiovascular problems. 
Moreover, the incidence of any event was not different in 
patients with reduced and preserved LVEF (12.1% and 
11.7%, respectively).  
Table 3.  Incidence of Events for 100 Patients/Year of Observation in our Patients according to LVEF 
 
  Total  Preserved Ejection Fraction  Reduced Ejection Fraction  Rates difference  p-value 
Total Death   1416 (9.01)  440 (8.96)  976 (9.08)  0.12 (-0.34-0.67)  0.7894 
Death due to CHF   912 (5.79)  281 (5.67)  631 (5.87)  0.20 (-0.40-0.79)  0.6756 
Admissions due to CHF   1513 (9.61)  467 (9.4)  1046 (9.74)  0.31 (-0.39-0.95)  0,5687 
Other CV admissions   418 (2.65)  129 (2.60)  289 (2.69)  0.09 (-0.58-1.12)  0.8765 
Admissions due to ACS   312 (1.98)  96 (1.94)  216 (2.01)  0.07 (-0.71-1.21)  0.8863 
Coronary revascularization   306 (1.96)  96 (1.94)  210 (1.96)  0.02 (-0.60-1.01)  0.9012 
Heart Transplant   52 (0.33)  7 (0.15)  45 (0.42)  0.27 (-1.01-1.78)  0.2346 
ICD implant   112 (0.71)  5 (0.10)  107 (0.99)  0.89 (-1.11-2.23)  0.078 
Any event   1880 (11.94)  582 (11.74)  1298 (12.08)  0.34 (-0.37-1.01)  0.5853 
 
 
Fig. (1). Kaplan-Meier unadjusted survival curves for patients with heart failure and preserved or reduced ejection fraction. 
 
Fig. (2). Kaplan-Meier unadjusted admission-free survival curves for patients with heart failure and preserved or reduced ejection fraction. 338    Current Cardiology Reviews, 2009, Vol. 5, No. 4  Castillo et al. 
  The overall survival rate was similar among patients with 
reduced  LVEF  and  patients with preserved LVEF (Fig (1)).  
The respective mortality rates were 79% and 78% at one 
year and 59% and 57% at five years. The admission and 
event-free survival likelihood was similar in both subgroups 
of patients (see Figs. (2 and 3)). 
 
Fig. (3). Kaplan-Meier unadjusted event-free survival curves for patients with heart failure and preserved or reduced ejection fraction. 
Table 4.  Univariate Cox Regression Analysis 
 
Characteristics  Deads (n=1416)  Alive (n=3304)  p-value 
Age, years (SD)  71(12)  64(10)  0.001 
Gender, Male (%)  66  65  0.44 
Hypertension(%) 60  54  0.05 
Hypercholesterolemia (%)  53  39  0.001 
Diabetes Mellitus (%)  36  30  0.003 
Prior AMI (%)  42  30  0.001 
Prior revascularization (%)  19  15  0.002 
Prior CHF admissio (%)  69  70  0.34 
NYHA Class III-IV (%)  27  22  0.05 
Ischemic aetiology (%)  48  39  0.001 
Atrial Fibrillation (%)  35  30  0.04 
EF, %(SD)  33(14)  38(13)  0.001 
EF<45% (%)  80  72  0.003 
Hb<12 gr/dl (%)  24  15  0.001 
Cr>2 mg/dl (%)  13  7  0.003 
Diuretics (%)  85  86  0.23 
Digoxin (%)  45  47  0.51 
ACE inhibitors (%)  74  78  0.06 
ARB-II (%)  21  22  0.56 
Spironolactone (%)  40  36  0.04 
Betablockers (%)  60  73  0.001 
Calcium channel blockers (%)  13  14  0.61 
Antiplatelets (%)  50  42  0.002 
Nitrates (%)  34  27  0.002 
Statins (%)  22  37  0.001 Outcome of Heart Failure with Preserved Ejection Fraction  Current Cardiology Reviews, 2009, Vol. 5, No. 4    339 
 Table  4 lists the results of univariate analyses carried out 
to determine the effects of several variables on survival. 
Age, hyperlipemia, anemia, diabetes, hypertension, NYHA 
class III-IV, atrial fibrillation, ejection fraction, renal 
dysfunction, no use of beta blockers or statins were all 
associated with poorer prognosis. Aetiology also affected 
survival (p<0.001): ischaemic aetiology was related with 
lower survival time. Multivariate analysis showed survival to 
be significantly influenced by age, ischaemic aetiology, 
anemia, renal dysfunction, beta blockers and statins (Table 
5).  
DISCUSSION 
  This registry provides a true overall picture of the 
characteristics and management of heart failure in Spain, 
within a very well-defined context: patients managed and 
followed-up in specific heart failure units or clinics. Herein, 
however, lies its main limitation, as the results can not be 
extrapolated to the general population. Studies of the 
differences in clinical characteristics, prognosis and the 
factors determining prognosis between patients with CHF 
with preserved and those with reduced LVEF have not all 
reached the same conclusions, probably related to 
differences in the design of the study, the methods used to 
evaluate cardiac function, the duration of follow-up, and in 
particular the target population (hospitalised or not).  
  The prevalence of patients with preserved LVEF in our 
registry (30%) is similar to that reported by other authors [7] 
but less than that found in the Framingham and in the 
Minnesota studies [3, 12]. In the EuroHeart Failure Survey 
the proportion of patients with preserved LVEF (considered 
as LVEF>40%) was 46% [8]. In all those studies, patients 
were enrolled after an index hospitalisation and this may not 
reflect the real natural history of heart failure with preserved 
ejection fraction. The criterion for normal systolic function 
in our registry is LVEF  45% according to the majority of 
recent studies and as suggested by the current ESC 
Guidelines [19].  
Clinical Characteristics and Therapy 
  We found differences between groups in terms of age, 
sex, aetiology and co-morbidities. Patients with heart failure 
and preserved LVEF are older, they are more commonly 
women and more frequently the aetiology is of hypertensive 
origin. Other Spanish group have reported similar results [8]. 
Patients with preserved LVEF had a significantly higher rate 
of atrial fibrillation which may be a precipitant of clinical 
deterioration in this setting.  
  Although there is currently no evidence available from 
randomised controlled trials on treatment of patients with 
preserved LVEF with ACE inhibitors or beta blockers, a 
considerable percentage of these patients were treated with 
such drugs. The percentage use of ACE inhibitors and beta 
blockers in patients with preserved LVEF was significantly 
lower than those with depressed LVEF, as clinical evidence 
is lacking but nevertheless still high, probably partly because 
of the ischaemic or hypertensive aetiology in many of these 
patients. These findings are consistent with those of the 
CHARM program in which the proportion of patients treated 
with diuretics, ACE inhibitors, spironolactone and digitalis 
decreased as LVEF increased [20]. In the recently published 
EuroHeart Failure Survey [8], the percentage of patients 
receiving ACE inhibitors or ARBs was 66% (81% in our 
registry) and the percentage of patients on beta blockers was 
37% (66% in our study). The study reported herein shows 
that achieving adequate therapy, similar to that seen in 
clinical trials, is possible in a large number of centres and 
units with a very variable organization and structure. In fact, 
no significant differences were detected in the pharma-
cological treatment provided by the different participating 
centres, irrespective they are general or community hospitals.  
Morbidity and Mortality 
  Our principal findings are related to morbidity and 
mortality. Patients with heart failure with preserved LVEF 
had complication rates that were similar to those of patients 
with reduced LVEF, including similar rates of death, 
admissions for worsening heart failure or for acute coronary 
syndrome. 
  Our study showed that patients with preserved LVEF had 
a high mortality rate during follow-up that were not 
significantly lower than those of patients with a reduced 
LVEF. Overall survival, admission due to worsening heart 
failure free survival and any cardiovascular event free 
survival were all similar between groups.  
  Traditionally prognosis of patients with heart failure was 
related to the ejection fraction and mortality of patients with 
reduced LVEF was much higher than those with preserved 
LVEF [12, 15, 20-23], however, some other studies reported 
the opposite [7, 14]. More recently, in a substudy of the 
CHARM program [20] LVEF was an important predictor of 
mortality and ejection fraction was a poorer predictor of 
Table 5.  Adjusted Hazard Ratios for Predictors of Mortality of Patients with Congestive Heart Failure from Multivariate Cox 
Regression Analysis 
 
Variable HR  95%  CI  p-value 
Age 1.68  1.18-2.05  0.0001 
Ischemic aetiology  1.09  1.04-1.95  0.008 
Anemia 1.62  1.23-2.01  0.0001 
Creatinine>2 mg/dl  1.41  1.10- 2.57  0.001 
Betablockers 0.81  0.48-0.95  0.003 
Statins 0.75  0.45-0.89  0.002 340    Current Cardiology Reviews, 2009, Vol. 5, No. 4  Castillo et al. 
cardiovascular outcomes in those with an LVEF above 45%. 
Bhatia et al. [7] reported similar one-year mortality rates of 
patients presenting with new-onset heart failure with 
LVEF<40% and LVEF>50%. In the study by Senni et al. 
[3], survival at 6 years was not statistically different in heart 
failure patients regardless of the level of systolic function. 
On the contrary, Owan et al. [13] reported a slightly better 
survival among patients with preserved ejection fraction 
(EF>50%) in a retrospective analysis of patients hospitalized 
with decompensated heart failure. In the EuroHeart Failure 
Survey [8] mortality at 12-week follow-up was 10% in 
patients with preserved LVEF and 12% in patients with 
reduced LVEF which is very similar to the mortality rate of 
our study. Nonetheless, the characteristics of these patients 
differed to those of our patients, since patients in the 
EuroHeart Failure Survey were older (69 years old and 66 
years old in our registry). Furthermore, patients in the 
EuroHeart Failure Survey were enrolled during hospita-
lisation due to heart failure whereas in our registry patients 
could be enrolled after admission to hospital due to heart 
failure or from the outpatient clinics. Thus, we cannot rule 
out the possibility of a selection bias due to the charac-
teristics of our registry and the criteria for inclusion of the 
patients in the heart failure clinics, which resulted in patients 
having a lower risk. 
  Some authors have underlined the effect of coronary 
artery disease on the survival of patients with heart failure. 
The presence of coronary artery disease is an important 
prognostic factor; when patients with coronary artery disease 
are excluded, the annual mortality of patients with preserved 
LVEF is only 2%-3%. O’Connor et al. [24] observed that the 
severity of ischaemic disease was an independent risk factor 
with respect to the mortality of such patients, whether left 
ventricular systolic function was preserved or not. In 
addition, when these authors compared survival rates of 
patients with heart failure and reduced systolic function to 
that of patients with heart failure and preserved systolic 
function, the difference disappeared when adjustment 
(among other variables). In contrast, other studies report no 
differences in prognosis associated with ischaemic and non-
ischaemic aetiologies [23, 25]. Setaro et al. [25] found that 
mortality at 7 years in patients with ischaemic and non-
ischaemic aetiology was the same (46%). In our study, the 
ischaemic aetiology was an independent risk factor.  
  Randomised studies which have compared the care 
provided by heart failure units with that afforded by the 
usual setting have shown a very significant reduction in 
admissions for worsening heart failure [26, 27]. Two 
randomised studies have recently been published which also 
showed a significant reduction in mortality, one of them a 
multicentre study in Spain [28, 29]. Thus, our results may be 
partly explained by such factor. However, the study by 
Atienza et al. [29] only included patients with heart failure 
who were discharged from the hospital and who therefore 
have a worse prognosis than patients in the BADAPIC 
registry, almost half of whom were outpatients with no 
recent admission. Despite these small differences between 
the two studies of randomised intervention and the 
observational BADAPIC study, the annual rates of mortality 
are between 5%-10% in all 3 studies, much lower than the 
annual mortality rates of 20%-30% in the previously 
mentioned population registries [2,8], and similar to those of 
clinical trials [15]. Thus, care of patients with heart failure in 
specialized clinics or units therefore seems to improve the 
prognosis of theses patients. 
Limitations 
  The main limitation of this registry, its observational and 
non-controlled character, introduces a possible selection bias 
when evaluating the results concerning the relative low rates 
of mortality and morbidity. The inclusion in our registry of 
both hospitalised and out-patients may affect the outcome as 
prognosis of out-patients is clearly better than those who 
have been admitted due to a decompensation. The results of 
randomised interventional studies with specific heart failure 
clinics support the idea that this type of care can improve the 
prognosis of patients with heart failure as educational and 
farmacological treatment may be improved. Our findings 
reinforce the need for new preventive strategies and new 
treatments specifically targeted at patients with congestive 
heart failure and preserved systolic function. 
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APPENDIX 
Participating Centres and Investigators of the BADAPIC 
Registry 
1)  Hospital General de Albacete: Pablo Domínguez 
Barrio. 
2)  Fundación Hospital Alcorcón: Elena España Barrio, 
Elena Batlle López. 
3)  Hospital General de Alicante: Francisco Sogorb Garri, 
Vicente Climent Payá. 
4)  Hospital de Antequera: Jesús Alvarez Rubiera, Alvaro 
Rubio Alcaide. 
5)  Hospital San Agustín de Avilés: Gerardo Casares 
García. 
6)  Hospital Infanta Cristina de Badajoz: León Martínez 
de la Concha. 
7)  Hospital Can Ruti de Badalona: José Lupón Roses, 
Teresa Pajarón Rodríguez. 
8)  Hospital San Eloy de Baracaldo: Javier Andrés 
Novales. 
9)  Hospital Vall d´ Hebrón de Barcelona: Stella Méndez, 
Enrique Galve. 
10)  Hospital de Terrassa: MA de Miguel, David López 
Gómez. 
11)  Hospital Mutua de Terrassa: Leandro Saenz, Amparo 
Alvarez. 
12)  Hospital Sant Pau de Barcelona: Domingo Ruiz 
Hidalgo, Josep Antón Montiel Dacosta. 
13)  Hospital Clinic i Provincial de Barcelona: Eulalia 
Roig Minguell, Alfredo Cupoletti Beange. Outcome of Heart Failure with Preserved Ejection Fraction  Current Cardiology Reviews, 2009, Vol. 5, No. 4    341 
14)  Hospital Sacrat Cor de Barcelona: Francesc Rossell 
Abaurrea, Cesar Morcillo Serra. 
15)  Hospital de Basurto de Bilbao: Nekane Murga 
Eizagaechaverria, Inmaculada Lluis Serret. 
16)  Hospital San Pedro de Alcántara de Cáceres: 
Concepción de la Concepción Palomino, Yolanda 
Porras Ramos. 
17)  Hospital General de Castellón: José Luis Diago 
Torrent, Alex Navarro Bellver. 
18)  Hospital Reina Sofía de Córdoba: Manuel Anguita 
Sánchez, Soledad Ojeda Pineda. 
19)  Hospital de Elche: Fernando García de Burgos y de 
Rico, Alejandro Jordá Torrent. 
20)  Hospital de Galdakao: Javier Zumalde Otegui, 
Alberto Salcedo Arruti. 
21)  Hospital de Gandía: Plácido Orosa Fernández, 
Catherine Lauwers Nelisen. 
22)  Hospital Virgen de las Nieves, Granada: Oscar Baun, 
José Luis Ventin Pereira. 
23)  Hospital General de Granollers, Barcelona: Santiago 
Montull Morer, Rosa Guitard. 
24)  Hospital del SAS de Jerez: José Carlos Vargas 
Machuca, Fernando García-Arboleya Puerto. 
25)  Hospital de Bellvitge: Nicolás Manito Lorite, Edgardo 
Kaplinsky. 
26)  Complejo Hospitalario de León: Julián Bayon 
Fernández, Manuela Montes Montes. 
27)  Hospital La Paz, Madrid: Isidoro González Maqueda, 
Gabriela Guzmán Martín, Llanos Soler Rangel, 
Francisco Arnalich Fernández. 
28)  Hospital Severo Ochoa, Leganés: Ana Isabel Huelmos 
Rodrigo, Angel Grande Ruiz. 
29)  Hospital de la Princesa, Madrid: Mercedes Fernández 
Escribano. 
30)  Hospital Costa del Sol, Marbella: Emilio González 
Cocina, Francisco Torres Calvo. 
31)  Hospital Carlos Haya, Málaga: Manuel de Mora 
Martín, José María Pérez Ruiz. 
32)  Hospital Virgen de la Victoria, Málaga: Eduardo de 
Teresa Galván, Encarnación Molero Campos, Manuel 
Jiménez Navarro. 
33)  Hospital Comarcal de Mendaro: Esther Recalde del 
Vigo, Nicolás Gurrutxaga Arrillaga. 
34)  Hospital Provincial Santa María Madre, Orense: 
Miguel A. Pérez de Juan, Manuel de Toro Santos. 
35)  Hospital Central de Asturias: Beatriz Díaz Molina, 
José Luis Rodríguez Lambert. 
36)  Hospital Río Carrión, Palencia: Fausto Librada 
Escribano. 
37)  Hospital General de Mallorca: Josefina Gutiérrez 
Alemany. 
38)  Hospital de Santa Bárbara, Puertollano: José Portillo 
Sánchez . 
39)  Hospital Sant Joan de Reus, Tarragona: Francesc 
Marimón Cortés, Oscar Palazón Molina. 
40)  Hospital Clinico Universitario de Salamanca: Pedro 
Luis Sánchez Fernández, Francisco Martín Herrero. 
41)  Hospital Donosita de San Sebastián: Ramón Querejeta 
Iraola, Eloy Sánchez Haya. 
42)  Hospital Marqués de Valdecilla, Santander: José 
Ramón Berrazueta Fernández. 
43)  Hospital Clínico Universitario de Santiago de 
Compostela: José R. González Juanatey, Inés Gómez 
Otero. 
44)  Hospital Universitario de Valme, Sevilla: Juan C. 
Beltrán Rodríguez, Luis Pastor Torres. 
45)  Hospital Virgen del Rocío, Sevilla: Angel Martínez 
Martínez. 
46)  Hospital Joan XXIII de Tarragona: Alfredo Bardají 
Ruiz, Ramón de Castro Aritmediz.  
47)  Hospital Sant Pau i Santa Tecla, Tarragona: Lluis 
Carles Olivan Sayrol, Juan Carlos Soriano Giménez. 
48)  Hospital Universitario de Canarias: Antonio Lara 
Padrón, Francisco Marrero Rodríguez. 
49)  Hospital General de Valencia: José Antonio Velasco 
Rami, Francisco Ridocci Soriano. 
50)  Hospital La Fe, Valencia: Luis Almenar, Joaquín 
Rueda Soriano. 
51)  Hospital Doctor Peset, Valencia: Begoña Sevilla 
Toral, Antonio Salvador Sanz. 
52)  Hospital Clinico Universitario de Valladolid: Luis de 
la Fuente Galán. 
53)  Hospital Mexoeiro de Vigo: Francisco Calvo Iglesias, 
José Luis Escribano Arias. 
54)  Hospital de Txagorritxu, Vitoria: Fernando Arós 
Borau. 
55)  Hospital Clinico Universitario Lozano Blesa, 
Zaragoza: Alfonso del Río Lligorit, Antonio San 
Pedro Feliú. 
56)  Hospital Miguel Servet, Zaragoza: Marisa Sanz Julve, 
Teresa Blasco Peiró. 
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